SynthesisOncotarget2017
The association between miR-423 rs6505162 polymorphism and cancer susceptibility: a systematic review and meta-analysis.
Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Associations between genetic polymorphisms inCancer biology & therapy · 2020Pooled it
- Inflammation and RNA-Related Polymorphisms in Resected Cholangiocarcinoma: Prognostic Associations in Intrahepatic and Perihilar Tumors.Journal of gastrointestinal cancer · 2026Article
- Article
- Single Nucleotide Polymorphisms in microRNA Genes and Colorectal Cancer Risk and Prognosis.Biomedicines · 2022Review
- MicroRNAs in Genetic Etiology of Human Diseases.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Genetic Polymorphism rs6505162 in MicroRNA-423 May Not Be Associated with Susceptibility of Breast Cancer: A Systematic Review and Meta-Analysis.Journal of oncology · 2021Review
- Functional mechanism and clinical implications of MicroRNA-423 in human cancers.Cancer medicine · 2020Review
- RNA-Seq profiling of deregulated miRs in CLL and their impact on clinical outcome.Blood cancer journal · 2020Article
- Polymorphism of miRNA and esophageal cancer risk: an updated systemic review and meta-analysis.OncoTargets and therapy · 2019Article
- Association of microRNA-423 rs6505162 C>A polymorphism with susceptibility and metastasis of colorectal carcinoma.Medicine · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The association between miR-423 polymorphism (C > A) and the risk of different cancers are still controversial. We performed a meta-analysis to clarify its association with multiple cancer risks. PubMed and Embase (as of 10th September, 2016) were searched. A total of 17 studies from 16 articles, consisting of 8,582 cases and 10,291 controls, were finally qualified and enrolled in this meta-analysis. The pooled results showed that the miR-423 AA genotype was associated with decreased cancer risk under the recessive model (odds ratio [OR] = 0.87, 95% confidence interval [CI]: 0.78~0.98, P = 0.020). However, this association became non-significant after excluding the study with the smallest odds ratio. Subgroup analyses revealed a significant decrease in risk of lung cancer (dominant model: OR = 0.73, 95 % CI: 0.60~0.89, P = 0.002; recessive model: OR = 0.59, 95 % CI: 0.37~0.95, P = 0.031). Our study indicates that miR-423 rs6505162 might be associated with a reduced risk of cancers, however, this finding need to be evaluated further in larger samples, especially subgroup analyses. In addition, cancer-specific functional studies are especially needed to reveal the underlying mechanisms between miR-423 and the etiology of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.